AnalystsBruce D. JacksonBruce D. Jackson's Stock Forecasts
AnalystsBruce D. Jackson
Analyst Ranking
Top 9%
#434 out of 5290 analysts
Average Return
+174.01%
Win Rate
76%13 out of 17
Risk vs Reward
Poor
Good
Bruce D. Jackson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Exact Sciences CorpEXAS | +2,580.11% | $69.59 | $1,865.09 | 2025-11-03 - 2026-03-24 | Strong Buy |
Humacyte IncHUMA | +130.64% | $0.61 | $1.40 | 2026-03-30 - 2026-06-03 | Buy |
Unicycive Therapeutics IncUNCY | +82.74% | $3.94 | $7.20 | 2025-09-14 - 2026-06-03 | Buy |
Harvard Bioscience IncHBIO | +44.80% | $4.49 | $6.50 | 2025-09-09 - 2026-06-03 | Buy |
Humacyte IncHUMA | +42.86% | $0.98 | $1.40 | 2026-01-20 - 2026-06-03 | Strong Buy |
Bruce D. Jackson Analyst Color
Get additional color on Bruce D. Jackson's coverage of popular stocks
Bruce D. Jackson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Humacyte IncHUMA | 4 | Buy | $2.00 | +42.86% | Maintains | 4 days ago |
Biofrontera IncBFRI | 1 | Buy | $3.00 | +204.26% | Downgrades | 17 days ago |
Abbott LaboratoriesABT | 1 | Strong Buy | $120.00 | +37.95% | Maintains | 2 months ago |
Unicycive Therapeutics IncUNCY | 2 | Buy | $15.00 | +108.33% | Maintains | 2 months ago |
Genelux CorpGNLX | 1 | Buy | $20.00 | +566.67% | Maintains | 3 months ago |
Harvard Bioscience IncHBIO | 3 | Buy | $6.00 | -7.69% | Maintains | 3 months ago |
Milestone Scientific IncMLSS | 1 | Buy | $1.00 | +156.41% | Maintains | 7 months ago |
Exact Sciences CorpEXAS | 1 | Strong Buy | $75.00 | -95.98% | Maintains | 7 months ago |
Belite Bio IncBLTE | 1 | Strong Buy | $132.00 | -3.81% | Maintains | 7 months ago |
Reviva Pharmaceuticals Holdings IncRVPH | 1 | Buy | $140.00 | +42,324.24% | Maintains | 9 months ago |
Clene IncCLNN | 1 | Strong Buy | $31.00 | +438.19% | Maintains | 9 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.